Tumor treating fields: a new frontier in cancer therapy

A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.

(2017) R. Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

(2012) Aaron Rulseh et al.   World Journal of Surgical Oncology

Tumor treating fields: concept, evidence and future

(2011) Miklos Pless et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters

(2010) Rosa S Schneiderman et al.   BMC CANCER

Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs

(2009) Eilon D. Kirson et al.   CLINICAL & EXPERIMENTAL METASTASIS

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

A Pilot Study with Very Low-Intensity, Intermediate-Frequency Electric Fields in Patients with Locally Advanced and/or Metastatic Solid Tumors

(2008) Marc Salzberg et al.   ONKOLOGIE